Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1986 Jun;29(6):1047–1052. doi: 10.1128/aac.29.6.1047

Selective antimicrobial modulation of the intestinal tract by norfloxacin in human volunteers and in gnotobiotic mice associated with a human fecal flora.

S Pecquet, A Andremont, C Tancrède
PMCID: PMC180498  PMID: 3729360

Abstract

Intestinal endogenous members of the family Enterobacteriaceae were eliminated in 12 human volunteers treated with 400 or 800 mg of oral norfloxacin per day for 5 days. No clones resistant to quinolone derivatives were isolated. Counts of aerotolerant streptococci were affected to various degrees, depending on their susceptibility to norfloxacin. During treatment, counts of anaerobes remained above 9.8 log10 CFU/g of feces. A total of 932 anaerobic isolates from the predominant flora (over 10(9) CFU/g) in fecal samples obtained before or during norfloxacin treatment were classified by a simple morphological and physiological scheme. The composition of this flora was fairly stable from one sample to another before treatment and was not substantially modified by norfloxacin. Intestinal resistance to colonization by exogenous microorganisms was studied in gnotobiotic mice associated with a human fecal flora. The composition of the fecal flora of the human donor and the fecal concentrations of norfloxacin in the volunteers were reproduced in the intestine of the mice. Resistance to colonization by exogenous microorganisms was reduced by norfloxacin for only 2 of 14 (14%) of the strains tested. These results suggest that norfloxacin is a good candidate for selective antimicrobial modulation of the intestinal tract in humans.

Full text

PDF
1047

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andremont A., Gerbaud G., Tancrède C., Courvalin P. Plasmid-mediated susceptibility to intestinal microbial antagonisms in Escherichia coli. Infect Immun. 1985 Sep;49(3):751–755. doi: 10.1128/iai.49.3.751-755.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Andremont A., Raibaud P., Tancrède C. Effect of erythromycin on microbial antagonisms: a study in gnotobiotic mice associated with a human fecal flora. J Infect Dis. 1983 Sep;148(3):579–587. doi: 10.1093/infdis/148.3.579. [DOI] [PubMed] [Google Scholar]
  3. Arank A., Syed S. A., Kenney E. B., Freter R. Isolation of anaerobic bacteria from human gingiva and mouse cecum by means of a simplified glove box procedure. Appl Microbiol. 1969 Apr;17(4):568–576. doi: 10.1128/am.17.4.568-576.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Best W. R. On the logarithmid transformation of intestinal bacterial counts. Am J Clin Nutr. 1970 Dec;23(12):1608–1609. doi: 10.1093/ajcn/23.12.1608. [DOI] [PubMed] [Google Scholar]
  5. Brumfitt W., Franklin I., Grady D., Hamilton-Miller J. M., Iliffe A. Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrob Agents Chemother. 1984 Nov;26(5):757–761. doi: 10.1128/aac.26.5.757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. CHABBERT Y., BOULINGRE H. Modifications pratiques concernant le dosage des antibiotiques en clinique. Rev Fr Etud Clin Biol. 1957 Jun;2(6):636–640. [PubMed] [Google Scholar]
  7. Ducluzeau R. Influence de l'espèce zoologique sur la microflore du tractus gastro-intestinal. Rev Immunol Ther Antimicrob. 1969 Oct-Dec;33(6):345–383. [PubMed] [Google Scholar]
  8. Ducluzeau R., Ladire M., Callut C., Raibaud P., Abrams G. D. Antagonistic effect of extremely oxygen-sensitive clostridia from the microflora of conventional mice and of Escherichia coli against Shigella flexneri in the digestive tract of gnotobiotic mice. Infect Immun. 1977 Aug;17(2):415–424. doi: 10.1128/iai.17.2.415-424.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Guiot H. F., van der Meer J. W., van Furth R. Selective antimicrobial modulation of human microbial flora: infection prevention in patients with decreased host defense mechanisms by selective elimination of potentially pathogenic bacteria. J Infect Dis. 1981 May;143(5):644–654. doi: 10.1093/infdis/143.5.644. [DOI] [PubMed] [Google Scholar]
  10. Hazenberg M. P., Bakker M., Both-Patoir H. C., Ruseler-van Embden J. G., Schröder A. M. Effect of sulphasalazine on the human intestinal flora. J Appl Bacteriol. 1982 Feb;52(1):103–107. doi: 10.1111/j.1365-2672.1982.tb04379.x. [DOI] [PubMed] [Google Scholar]
  11. Hazenberg M. P., Van de Boom M., Bakker M., Van de Merwe J. P. Effect of antibiotics on the human intestinal flora in mice. Antonie Van Leeuwenhoek. 1983 Jun;49(2):97–109. doi: 10.1007/BF00393667. [DOI] [PubMed] [Google Scholar]
  12. Hentges D. J., Stein A. J., Casey S. W., Que J. U. Protective role of intestinal flora against infection with Pseudomonas aeruginosa in mice: influence of antibiotics on colonization resistance. Infect Immun. 1985 Jan;47(1):118–122. doi: 10.1128/iai.47.1.118-122.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Holmberg S. D., Osterholm M. T., Senger K. A., Cohen M. L. Drug-resistant Salmonella from animals fed antimicrobials. N Engl J Med. 1984 Sep 6;311(10):617–622. doi: 10.1056/NEJM198409063111001. [DOI] [PubMed] [Google Scholar]
  14. KHEDER J., WHEELER W. E. COLISTIN SUPPRESSION OF ESCHERICHIA COLI IN STOOLS. II. REDUCTION OF FECAL EXCRETION OF NON-ENTEROPATHOGENIC ESCHERICHIA COLI IN INFANTS WITH DIARRHEA. Am J Dis Child. 1964 Sep;108:278–282. doi: 10.1001/archpedi.1964.02090010280010. [DOI] [PubMed] [Google Scholar]
  15. Leonard F., Andremont A., Tancrede C. In vivo activity of nifurzide and nifuroxazide in intestinal bacteria in man and gnotobiotic mice. J Appl Bacteriol. 1985 Jun;58(6):545–553. doi: 10.1111/j.1365-2672.1985.tb01710.x. [DOI] [PubMed] [Google Scholar]
  16. Muytjens H. L., van Veldhuizen G. L., Welling G. W., van der Ros-van de Repe J., Boerema H. B., van der Waaij D. Selective decontamination of the digestive tract by pipemidic acid. Antimicrob Agents Chemother. 1983 Dec;24(6):902–904. doi: 10.1128/aac.24.6.902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Norrby S. R., Jonsson M. Antibacterial activity of norfloxacin. Antimicrob Agents Chemother. 1983 Jan;23(1):15–18. doi: 10.1128/aac.23.1.15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Riley L. W., Cohen M. L., Seals J. E., Blaser M. J., Birkness K. A., Hargrett N. T., Martin S. M., Feldman R. A. Importance of host factors in human salmonellosis caused by multiresistant strains of Salmonella. J Infect Dis. 1984 Jun;149(6):878–883. doi: 10.1093/infdis/149.6.878. [DOI] [PubMed] [Google Scholar]
  19. Tancrède C. H., Andremont A. O. Bacterial translocation and gram-negative bacteremia in patients with hematological malignancies. J Infect Dis. 1985 Jul;152(1):99–103. doi: 10.1093/infdis/152.1.99. [DOI] [PubMed] [Google Scholar]
  20. Wade J. C., de Jongh C. A., Newman K. A., Crowley J., Wiernik P. H., Schimpff S. C. Selective antimicrobial modulation as prophylaxis against infection during granulocytopenia: trimethoprim-sulfamethoxazole vs. nalidixic acid. J Infect Dis. 1983 Apr;147(4):624–634. doi: 10.1093/infdis/147.4.624. [DOI] [PubMed] [Google Scholar]
  21. de Vries-Hospers H. G., Welling G. W., Swabb E. A., van der Waaij D. Selective decontamination of the digestive tract with aztreonam: a study of 10 healthy volunteers. J Infect Dis. 1984 Nov;150(5):636–642. doi: 10.1093/infdis/150.5.636. [DOI] [PubMed] [Google Scholar]
  22. van der Waaij D. Colonization resistance of the digestive tract: clinical consequences and implications. J Antimicrob Chemother. 1982 Oct;10(4):263–270. doi: 10.1093/jac/10.4.263. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES